Guidelines for the management of CDH1 carriers state BRRM can be considered in hereditary lobular breast cancer and hereditary diffuse gastric cancer, however it is not generally recommended for those aged under 30 years or over 60 years [27]. This evidence concerns the gene CDH1 and Familial gastric cancer.